Literature DB >> 12594038

Molecular and phylogenetic characterization of Zyx102, a Drosophila orthologue of the zyxin family that interacts with Drosophila Enabled.

Patricia J Renfranz1, Sarah E Siegrist, Beth E Stronach, Teresita Macalma, Mary C Beckerle.   

Abstract

Adherens junctions, which are cadherin-mediated junctions between cells, and focal adhesions, which are integrin-mediated junctions between cells and the extracellular matrix, are protein complexes that link the actin cytoskeleton to the plasma membrane and, in turn, to the extracellular environment. Zyxin is a LIM domain protein that is found in vertebrate adherens junctions and focal adhesions. Zyxin's molecular architecture and binding partner repertoire suggest roles in actin assembly and dynamics, cell motility, and nuclear-cytoplasmic communication. In order to study the function of zyxin in development, we have identified a zyxin orthologue in Drosophila melanogaster that we have termed Zyx102. Like its vertebrate counterparts, Zyx102 displays three carboxy-terminal LIM domains, a potential nuclear export signal, and three proline-rich motifs, one of which matches the consensus for mediating an interaction with Ena/VASP (Drosophila Enabled/Vasodilator-stimulated phosphoprotein) proteins. Here we show that Zyx102 and Enabled (Ena), the Drosophila member of the Ena/VASP family, can interact specifically in vitro and that this interaction does not occur when a particular mutant form of Ena, encoded by the lethal ena210 allele, is used. Lastly, we show that the zyx102 gene and Drosophila Ena are co-expressed during oogenesis and early embryogenesis, indicating that the two proteins may be able to interact during the development of the Drosophila egg chamber and early embryo.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12594038     DOI: 10.1016/s0378-1119(02)01173-3

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  8 in total

1.  The cytoskeletal regulator zyxin is required for viability in Drosophila melanogaster.

Authors:  Patricia J Renfranz; Elizabeth Blankman; Mary C Beckerle
Journal:  Anat Rec (Hoboken)       Date:  2010-09       Impact factor: 2.064

2.  Ajuba LIM proteins are negative regulators of the Hippo signaling pathway.

Authors:  Meghna Das Thakur; Yunfeng Feng; Radhika Jagannathan; Midori J Seppa; James B Skeath; Gregory D Longmore
Journal:  Curr Biol       Date:  2010-03-18       Impact factor: 10.834

Review 3.  Regulation of the Hippo pathway in cancer biology.

Authors:  Sungho Moon; So Yeon Park; Hyun Woo Park
Journal:  Cell Mol Life Sci       Date:  2018-03-30       Impact factor: 9.261

4.  Zyxin links fat signaling to the hippo pathway.

Authors:  Cordelia Rauskolb; Guohui Pan; B V V G Reddy; Hyangyee Oh; Kenneth D Irvine
Journal:  PLoS Biol       Date:  2011-06-07       Impact factor: 8.029

5.  Stretch-induced actin remodeling requires targeting of zyxin to stress fibers and recruitment of actin regulators.

Authors:  Laura M Hoffman; Christopher C Jensen; Aashi Chaturvedi; Masaaki Yoshigi; Mary C Beckerle
Journal:  Mol Biol Cell       Date:  2012-03-28       Impact factor: 4.138

6.  Cell density-dependent proteolysis by HtrA1 induces translocation of zyxin to the nucleus and increased cell survival.

Authors:  Fabio Sabino; Elizabeta Madzharova; Ulrich Auf dem Keller
Journal:  Cell Death Dis       Date:  2020-08-21       Impact factor: 8.469

7.  ZYX-1, the unique zyxin protein of Caenorhabditis elegans, is involved in dystrophin-dependent muscle degeneration.

Authors:  Claire Lecroisey; Nicolas Brouilly; Hiroshi Qadota; Marie-Christine Mariol; Nicolas C Rochette; Edwige Martin; Guy M Benian; Laurent Ségalat; Nicole Mounier; Kathrin Gieseler
Journal:  Mol Biol Cell       Date:  2013-02-20       Impact factor: 4.138

8.  C. elegans Enabled exhibits novel interactions with N-WASP, Abl, and cell-cell junctions.

Authors:  Mark Sheffield; Timothy Loveless; Jeff Hardin; Jonathan Pettitt
Journal:  Curr Biol       Date:  2007-10-11       Impact factor: 10.834

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.